

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma

Sabrina Priol^{a,*}, Barbara Cortelazzi^b, Valentina Dal Col^a, Domenico Marson^a, Erik Laurini^a, Maurizio Fermeglia^a, Lisa Licitra^c, Silvana Pilotti^b, Paolo Bossi^{c,#}, Federica Perrone^{b,*,#}

^aMolecular Simulation Engineering (MOSE) Laboratory, DEA, University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy.

^bLaboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133 Milan, Italy.

^cHead and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.

SUPPLEMENTARY MATERIAL



Figure S1 - Clinical appearance of the suprascapular BCC at diagnosis (left) and after 6 months of vismodegib (right).